ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
12 hedge funds and large institutions have $30.5M invested in ESSA Pharma in 2016 Q3 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
7% less capital invested
Capital invested by funds: $32.7M → $30.5M (-$2.22M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$44K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$267 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$95K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$18.7K |
EPIX Hedge Fund Activity: Q3 2016 in Review
12 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q3 2016, worth a combined $30.5M — down 6.8% from $32.7M a quarter earlier.
Fund positioning in EPIX was balanced in Q3 2016: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Acuta Capital Partners, adding an estimated $44K. The largest seller was Deerfield Management, cutting an estimated $95K.
- 12 institutional investors held ESSA Pharma (EPIX) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $30.5M of ESSA Pharma stock for Q3 2016, down 6.8% quarter-over-quarter.
- 0 funds opened new ESSA Pharma positions in Q3 2016 and 0 closed out.
- The largest ESSA Pharma buyer in Q3 2016 was Acuta Capital Partners, an estimated $44K added.
- The largest ESSA Pharma seller in Q3 2016 was Deerfield Management, an estimated $95K sold.
Based on aggregated 13F filings for Q3 2016.